Deals Rumor Mill: AstraZeneca, ICBC, Johnson & Johnson
By Chelsea Naso
Law360, New York (November 8, 2013, 3:53 PM ET) -- AstraZeneca may be looking to increase its stake in its diabetes joint venture with Bristol-Myers Squibb Co. following on the heels of Bristol’s announcement Thursday it would no longer conduct research to discover new drugs for diabetes, hepatitis C and neuroscience, a Citi analyst told Reuters. The analyst estimated Bristol’s diabetes business could be worth up to $600 billion, which would bolster AstraZeneca’s per share earnings by between 1 and 5 percent.
South African lender Standard Bank is reportedly in talks to ditch its controlling stake in its...